Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Ascentage Pharma Group International (AAPG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: AAPG (3-star) is a STRONG-BUY. BUY since 52 days. Profits (54.90%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
Analysis of Past Performance
Type Stock | Historic Profit 54.9% | Avg. Invested days 52 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.35B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1 | 52 Weeks Range 16.50 - 40.81 | Updated Date 05/15/2025 |
52 Weeks Range 16.50 - 40.81 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.17 |
Earnings Date
Report Date 2025-07-03 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -39.9% | Operating Margin (TTM) 22.82% |
Management Effectiveness
Return on Assets (TTM) -7.14% | Return on Equity (TTM) -52.38% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1665238458 | Price to Sales(TTM) 7.03 |
Enterprise Value 1665238458 | Price to Sales(TTM) 7.03 | ||
Enterprise Value to Revenue 13.44 | Enterprise Value to EBITDA - | Shares Outstanding 348267008 | Shares Floating 174845965 |
Shares Outstanding 348267008 | Shares Floating 174845965 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Ascentage Pharma Group International
Company Overview
History and Background
Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. While founded in China in 2009, it has a US presence. Milestones include the development of core drug candidates and strategic collaborations.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing innovative therapies for hematologic malignancies and solid tumors.
- Chronic Hepatitis B (CHB): Develops therapies to address unmet needs in chronic hepatitis B treatment.
- Age-Related Diseases: Research and development of novel therapies targeting age-related diseases.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is typically hierarchical, with departments focused on R&D, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Olverembatinib (HQP1351): A third-generation BCR-ABL inhibitor approved in China for treatment-resistant chronic myeloid leukemia (CML). Market share data specific to the US market is not readily available, as the drug is not yet FDA-approved. Competitors include Novartis' Tasigna and Sprycel, Bristol Myers Squibb's Sprycel.
- APG-115 (Lisaftoclax): A Bcl-2 inhibitor in clinical development for various hematological malignancies. No revenue data is publicly available. Competitors include AbbVie's Venclexta.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The oncology market is rapidly growing, driven by increasing cancer incidence and advances in treatment options.
Positioning
Ascentage Pharma is positioning itself as an innovative biopharmaceutical company with a focus on developing novel targeted therapies for cancer and other diseases. Its competitive advantage lies in its proprietary drug discovery platform and clinical development expertise.
Total Addressable Market (TAM)
The global oncology drug market is estimated to be worth hundreds of billions of dollars. Ascentage Pharma aims to capture a significant portion of this market with its innovative therapies, focusing on targeted therapies with potential for higher efficacy and fewer side effects.
Upturn SWOT Analysis
Strengths
- Innovative drug discovery platform
- Strong pipeline of novel drug candidates
- Experienced management team
- Strategic partnerships with leading pharmaceutical companies
Weaknesses
- Limited commercial infrastructure in the US market
- Reliance on external funding for R&D
- High R&D costs and long development timelines
- Dependence on key drug candidates for future growth
Opportunities
- Expansion into new therapeutic areas
- FDA Approval of drugs in clinical trials
- Strategic acquisitions of complementary technologies or companies
- Partnerships with larger pharmaceutical companies for commercialization
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays in drug approval
- Patent expiration and generic competition
- Economic downturns and changes in healthcare policy
Competitors and Market Share
Key Competitors
- NVS
- BMY
- ABBV
Competitive Landscape
Ascentage Pharma faces intense competition from established pharmaceutical companies with larger resources and broader product portfolios. Its advantages include its innovative drug discovery platform and focus on developing targeted therapies for unmet medical needs. Its disadvantages include its smaller size and limited commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by progress in clinical trials, regulatory approvals in China, and expansion of the pipeline.
Future Projections: Future growth is dependent on the success of ongoing clinical trials, regulatory approvals in key markets (including the US), and commercialization of new products. Analyst estimates are not available.
Recent Initiatives: Recent initiatives include advancing clinical trials for key drug candidates, seeking regulatory approvals in new markets, and expanding partnerships with other pharmaceutical companies.
Summary
Ascentage Pharma is an innovative biopharmaceutical company with a promising pipeline, but it faces significant challenges in a competitive industry. Its strength lies in its novel drug discovery platform and its established presence in China. The company needs to secure US FDA approvals. It also needs to carefully manage its cash flow and address competition from larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings of Competitors
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It should not be considered financial advice. Market share data is estimated and may not be precise. Financial metrics are difficult to interpret due to primary listing outside the US.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ascentage Pharma Group International
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-01-24 | Co-Founder, Chairman & CEO Dr. Dajun Yang M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 567 | Website https://www.ascentage.cn |
Full time employees 567 | Website https://www.ascentage.cn | ||
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is also involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.